JP2008517991A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517991A5 JP2008517991A5 JP2007538524A JP2007538524A JP2008517991A5 JP 2008517991 A5 JP2008517991 A5 JP 2008517991A5 JP 2007538524 A JP2007538524 A JP 2007538524A JP 2007538524 A JP2007538524 A JP 2007538524A JP 2008517991 A5 JP2008517991 A5 JP 2008517991A5
- Authority
- JP
- Japan
- Prior art keywords
- effective amount
- therapeutically effective
- pld
- combination
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000001802 infusion Methods 0.000 claims 5
- 238000010253 intravenous injection Methods 0.000 claims 5
- 229940079593 drugs Drugs 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960004679 Doxorubicin Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 230000002195 synergetic Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62216304P | 2004-10-26 | 2004-10-26 | |
PCT/GB2005/050189 WO2006046080A2 (fr) | 2004-10-26 | 2005-10-26 | Traitements anticancereux |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009219607A Division JP2009292850A (ja) | 2004-10-26 | 2009-09-24 | 抗癌治療 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2008517991A JP2008517991A (ja) | 2008-05-29 |
JP2008517991A5 true JP2008517991A5 (fr) | 2008-11-13 |
JP4554684B2 JP4554684B2 (ja) | 2010-09-29 |
Family
ID=36096124
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007538524A Active JP4554684B2 (ja) | 2004-10-26 | 2005-10-26 | 抗癌治療 |
JP2009219607A Pending JP2009292850A (ja) | 2004-10-26 | 2009-09-24 | 抗癌治療 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009219607A Pending JP2009292850A (ja) | 2004-10-26 | 2009-09-24 | 抗癌治療 |
Country Status (27)
Country | Link |
---|---|
US (1) | US20090117176A1 (fr) |
EP (1) | EP1827500B1 (fr) |
JP (2) | JP4554684B2 (fr) |
KR (1) | KR101287918B1 (fr) |
CN (1) | CN101119750B (fr) |
AT (1) | ATE430586T1 (fr) |
AU (1) | AU2005298364B2 (fr) |
BR (1) | BRPI0518250A2 (fr) |
CA (1) | CA2582452C (fr) |
CY (1) | CY1110329T1 (fr) |
DE (1) | DE602005014380D1 (fr) |
DK (1) | DK1827500T3 (fr) |
ES (1) | ES2326825T3 (fr) |
HK (1) | HK1107766A1 (fr) |
HR (1) | HRP20090345T1 (fr) |
IL (1) | IL182352A (fr) |
MX (1) | MX2007004744A (fr) |
NO (1) | NO328958B1 (fr) |
NZ (1) | NZ554765A (fr) |
PL (1) | PL1827500T3 (fr) |
PT (1) | PT1827500E (fr) |
RS (1) | RS50822B (fr) |
RU (1) | RU2359700C2 (fr) |
SI (1) | SI1827500T1 (fr) |
UA (1) | UA87877C2 (fr) |
WO (1) | WO2006046080A2 (fr) |
ZA (1) | ZA200703396B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
CZ20031327A3 (cs) * | 2000-11-06 | 2003-11-12 | Pharma Mar, S. A. | Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu |
GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
CA2544320A1 (fr) | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Utilisation d'une combinaison d'et-743 et de 5-fluorouracile pour traiter le cancer |
CN1897949A (zh) * | 2003-11-14 | 2007-01-17 | 马尔药品公司 | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 |
SI1658848T1 (sl) | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Formulacije vsebujoäśe ekteinascidin in disaharid |
GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
KR101376634B1 (ko) * | 2006-06-19 | 2014-03-27 | 더 존스 홉킨스 유니버시티 | 리포좀아제에 의한 치료제의 종양특이적 전달 |
AU2008313634A1 (en) * | 2007-10-19 | 2009-04-23 | Pharma Mar, S.A. | Prognostic molecular markers for ET-743 treatment |
US11110108B2 (en) * | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
RU2657835C1 (ru) * | 2017-11-28 | 2018-06-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" | Способ получения системы для доставки противоопухолевого препарата в клетки опухоли |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
US6124293A (en) * | 1998-04-06 | 2000-09-26 | The Board Of Trustees Of The University Of Illinois | Semi-synthetic ecteinascidins |
US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
MY130271A (en) * | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
US20020028237A1 (en) * | 2000-04-20 | 2002-03-07 | Colbern Gail T. | Method for reducing toxicity of a cytotoxic agent |
US7247892B2 (en) * | 2000-04-24 | 2007-07-24 | Taylor Geoff W | Imaging array utilizing thyristor-based pixel elements |
US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
EP1356097A2 (fr) * | 2000-08-11 | 2003-10-29 | City of Hope | Agent anti neoplasique et-743 inhibant la trans-activation par sxr |
KR100834138B1 (ko) * | 2000-10-31 | 2008-06-02 | 파르마 마르, 에스.에이. | 카할라리드 에프 |
CZ20031327A3 (cs) * | 2000-11-06 | 2003-11-12 | Pharma Mar, S. A. | Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu |
EP1368034A1 (fr) * | 2001-03-06 | 2003-12-10 | Bristol-Myers Squibb Company | Procede et forme posologique pour le traitement de tumeurs par administration de tegafur, d'uracile, d'acide folinique, de paclitaxel et de carboplatine |
KR100915741B1 (ko) * | 2001-06-15 | 2009-09-04 | 코너스톤 파마슈티칼스 | 표적 조직 및 세포를 치료하기에 유용한 나노입자를함유하는 약제학적 및 진단학적 조성물 |
CA2462502A1 (fr) * | 2001-10-19 | 2003-05-15 | Pharma Mar, S.A. | Utilisation amelioree de compose anti-tumoral dans le traitement des cancers |
US20040019027A1 (en) * | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
AU2003253954A1 (en) * | 2002-07-16 | 2004-02-02 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Support bra for ultrasonic breast scanner |
GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
CA2544320A1 (fr) * | 2003-11-13 | 2005-06-02 | Pharma Mar, S.A.U. | Utilisation d'une combinaison d'et-743 et de 5-fluorouracile pour traiter le cancer |
CN1897949A (zh) * | 2003-11-14 | 2007-01-17 | 马尔药品公司 | 包含使用et-743和紫杉醇来治疗癌症的联合疗法 |
GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
US20050129752A1 (en) * | 2003-12-15 | 2005-06-16 | Tty Biopharm Limited Company | Use and manufacturing process for liposomal doxorubicin pharmaceutical composition |
WO2006005602A2 (fr) * | 2004-07-09 | 2006-01-19 | Pharma Mar, S.A. | Marqueurs moleculaires de pronostic |
SI1658848T1 (sl) * | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Formulacije vsebujoäśe ekteinascidin in disaharid |
US20090170860A1 (en) * | 2005-11-25 | 2009-07-02 | Pharma Mar, S.A., Sociedad Unipersonal | Use of PARP-1 Inhibitors |
US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
EP2023931A2 (fr) * | 2006-05-12 | 2009-02-18 | Pharma Mar S.A. | Traitements anticancéreux avec une combinaison de docétaxel et ecteinascidine |
-
2005
- 2005-10-26 SI SI200530688T patent/SI1827500T1/sl unknown
- 2005-10-26 RU RU2007119545/14A patent/RU2359700C2/ru active
- 2005-10-26 RS RSP-2009/0311A patent/RS50822B/sr unknown
- 2005-10-26 NZ NZ554765A patent/NZ554765A/en unknown
- 2005-10-26 WO PCT/GB2005/050189 patent/WO2006046080A2/fr active Application Filing
- 2005-10-26 UA UAA200705818A patent/UA87877C2/ru unknown
- 2005-10-26 KR KR1020077009355A patent/KR101287918B1/ko active IP Right Grant
- 2005-10-26 PT PT05803151T patent/PT1827500E/pt unknown
- 2005-10-26 BR BRPI0518250-6A patent/BRPI0518250A2/pt not_active Application Discontinuation
- 2005-10-26 AT AT05803151T patent/ATE430586T1/de active
- 2005-10-26 EP EP05803151A patent/EP1827500B1/fr not_active Revoked
- 2005-10-26 ES ES05803151T patent/ES2326825T3/es active Active
- 2005-10-26 JP JP2007538524A patent/JP4554684B2/ja active Active
- 2005-10-26 CN CN2005800369316A patent/CN101119750B/zh active Active
- 2005-10-26 PL PL05803151T patent/PL1827500T3/pl unknown
- 2005-10-26 US US11/577,790 patent/US20090117176A1/en not_active Abandoned
- 2005-10-26 CA CA2582452A patent/CA2582452C/fr active Active
- 2005-10-26 DE DE602005014380T patent/DE602005014380D1/de active Active
- 2005-10-26 AU AU2005298364A patent/AU2005298364B2/en active Active
- 2005-10-26 MX MX2007004744A patent/MX2007004744A/es active IP Right Grant
- 2005-10-26 DK DK05803151T patent/DK1827500T3/da active
-
2007
- 2007-04-01 IL IL182352A patent/IL182352A/en active IP Right Grant
- 2007-04-25 ZA ZA200703396A patent/ZA200703396B/xx unknown
- 2007-05-16 NO NO20072543A patent/NO328958B1/no unknown
-
2008
- 2008-01-22 HK HK08100804.8A patent/HK1107766A1/xx unknown
-
2009
- 2009-06-15 HR HR20090345T patent/HRP20090345T1/xx unknown
- 2009-08-03 CY CY20091100818T patent/CY1110329T1/el unknown
- 2009-09-24 JP JP2009219607A patent/JP2009292850A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008517991A5 (fr) | ||
CA2582452A1 (fr) | Doxorubicine liposomale pegylee en combinaison avec l'ecteinascidine 743 | |
JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
JP2008520544A5 (ja) | 癌関連疲労の治療または予防のための医薬の製造への使用方法 | |
HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
JP2009539769A5 (fr) | ||
IL145487A0 (en) | Apomorphine and sildenafil composition | |
RU2012106620A (ru) | Комбинации и способы введения терапевтических средств и комбинированной терапии | |
JP2010519224A5 (fr) | ||
JP2002544231A5 (fr) | ||
WO2005094899A8 (fr) | Traitement de cancers par un antisens anti-clusterine | |
KR101900520B1 (ko) | 복합 조성물 | |
JP2010526837A5 (fr) | ||
JP2006514092A5 (fr) | ||
RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
ES2267841T3 (es) | Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer. | |
JP2003514025A5 (fr) | ||
JP2005508963A5 (fr) | ||
CA2474430A1 (fr) | Polytherapie combinant un agent thrombolytique et du levosimendane pour le traitement de l'infractus aigu du myocarde | |
CA2450915A1 (fr) | Utilisation de levosimendane et d'un antagoniste du recepteur beta-adrenergique pour traiter les defaillances cardiaques | |
JP2015510945A5 (fr) | ||
CA2516458A1 (fr) | Utilisation de composes de kahalalide pour la fabrication d'un medicament pour le traitement de psoriasis | |
RU2010140888A (ru) | Улучшенные противораковые терапии |